Univariate analysis | Multivariable analysis | ||||||
RR* | P value | 95% CI | AUC | RR* | P value | 95% CI | |
Outcome: anti-RBD-IgG concentration >1 S/CO | |||||||
Female | 1.18 | 0.280 | 0.88 to 1.58 | 0.60 | 1.23 | 0.125 | 0.94 to 1.62 |
Age (years)† | 0.93 | <0.001 | 0.89 to 0.97 | 0.89 | 0.94 | 0.001 | 0.90 to 0.97 |
MTX monotherapy | 1.00 | 0.63 | 1.00 | ||||
MTX+prednisolone | 0.79 | 0.284 | 0.51 to 1.22 | 0.86 | 0.415 | 0.60 to 1.24 | |
MTX combination±prednisolone | 1.05 | 0.687 | 0.84 to 1.30 | 1.04 | 0.693 | 0.86 to 1.25 | |
MTX dose (mg) | 0.99 | 0.688 | 0.97 to 1.02 | 0.54 | |||
MTX-hold | 1.39 | 0.006 | 1.10 to 1.76 | 0.74 | 1.27 | 0.020 | 1.04 to 1.56 |
Vaccine interval | 1.006 | 0.016 | 1.001 to 1.010 | 0.75 | 1.004 | 0.024 | 1.0006 to 1.008 |
Outcome: neutralisation capacity ≥30% | |||||||
Female | 1.36 | 0.055 | 0.99 to 1.87 | 0.72 | 1.43 | 0.012 | 1.08 to 1.90 |
Age (years)† | 0.96 | 0.008 | 0.92 to 0.99 | 0.77 | 0.96 | 0.018 | 0.93 to 0.99 |
MTX monotherapy | 1.00 | 0.68 | 1.00 | ||||
MTX+prednisolone | 0.75 | 0.194 | 0.49 to 1.15 | 0.75 | 0.099 | 0.53 to 1.06 | |
MTX combination±prednisolone | 1.04 | 0.641 | 0.87 to 1.25 | 0.98 | 0.838 | 0.84 to 1.15 | |
MTX dose (mg) | 0.99 | 0.452 | 0.97 to 1.01 | 0.58 | |||
MTX-hold | 1.28 | 0.019 | 1.04 to 1.57 | 0.72 | 1.17 | 0.039 | 1.00 to 1.38 |
Vaccine interval | 1.002 | 0.235 | 0.999 to 1.006 | 0.63 | 1.001 | 0.423 | 0.998 to 1.004 |
*RR was estimated by a Poisson generalised linear model with robust error variances and log link function in univariate and multivariable analyses according to Zou.19
†RR for increase by 5 years.
AUC, area under the curve; MTX, methotrexate; RR, relative risk; S/CO, signal/cut-off.